Four out of 10 evaluable patients showed clinical response (PGA score ≤ 3), three of whom achieved complete closure of target lesion Treatment was well tolerated; no adverse events associated with ...
Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers JENA, Germany, June 13, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), an innovative ...
Interim results will be available by the end of 2021 with final results expected in 2022 Initial positive data from the first 5 patients previously announced in Q1 2020 JENA, Germany, April 15, 2021 ...
JENA, Germany, Feb. 26, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, ...
(RTTNews) - Shares of InflaRx N.V. (IFRX) have been on a roll since the beginning of this year, hitting new highs. Germany-based InflaRx is a clinical-stage biopharmaceutical company focused on ...
Shares of InflaRx fell 84% in premarket trade Wednesday after the biotech said its drug for an inflammatory skin disorder called hidradenitis suppurativa failed to show a statistically significant ...
Target enrollment of 18 patients reached across three different dose groups Interim results will be available by the end of 2021 with final results expected in 2022 Initial positive data from the ...
Four out of 10 evaluable patients showed clinical response (PGA score ≤ 3), three of whom achieved complete closure of target lesion Treatment was well tolerated; no adverse events associated with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback